A single-arm study evaluating the relative dose intensity of IV CMF [cyclophosphamide + methotrexate + fluorouracil] given on day 1 and day 8 with pegfilgrastim support in subjects with stage I-III breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2010
At a glance
- Drugs Cyclophosphamide; Fluorouracil; Methotrexate
- Indications Breast cancer
- Focus Adverse reactions
- 25 Feb 2010 Trial location (Spain) added as reported by ClinicalTrials.gov record.
- 11 Nov 2005 New trial record.